Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00145249
First received: September 2, 2005
Last updated: May 10, 2012
Last verified: October 2009
Results First Received: March 18, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Cryptococcal Meningitis
Interventions: Drug: Amphotericin B
Drug: Fluconazole

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
AmphoB Standard Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
AmphoB+Fluc400 Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
AmphoB + Fluc800 Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
Total Total of all reporting groups

Baseline Measures
    AmphoB Standard     AmphoB+Fluc400     AmphoB + Fluc800     Total  
Number of Participants  
[units: participants]
  45     47     49     141  
Age  
[units: participants]
       
<=18 years     0     0     1     1  
Between 18 and 65 years     45     47     47     139  
>=65 years     0     0     1     1  
Age  
[units: years]
Mean ± Standard Deviation
  37.1  ± 8.47     36.5  ± 8.21     35.9  ± 9.44     36.5  ± 8.69  
Gender  
[units: participants]
       
Female     16     15     18     49  
Male     29     32     31     92  
Region of Enrollment  
[units: participants]
       
United States     14     14     14     42  
Thailand     31     33     35     99  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug   [ Time Frame: Day 100 ]

2.  Primary:   Number of Dose-limiting Toxicities Attributed to Treatment Regimens   [ Time Frame: Day 100 ]

3.  Secondary:   Number of Deaths   [ Time Frame: 14, 42, and 70 days ]

4.  Secondary:   Number of Subjects With Cerebrospinal Fluid (CSF) Culture Conversion at Multiple Time Points   [ Time Frame: Baseline, 14, 42, and 70 days ]

5.  Secondary:   Number of Subjects Meeting the Key Efficacy Endpoint of Treatment Success   [ Time Frame: 14, 42, and 70 days ]

6.  Secondary:   Number of Subjects Reporting Immune Reconstitution Inflammatory Syndrome (IRIS)   [ Time Frame: 14, 42, and 70 days ]

7.  Secondary:   Mean Days of Hospitalization   [ Time Frame: 7, 14, 42, and 70 days ]

8.  Secondary:   Number of Cryptococcal Isolates With Antifungal Susceptibility   [ Time Frame: Days 14 and 70 ]

9.  Secondary:   Mean Change in Neurological Exam Score From Baseline - Day 14   [ Time Frame: Baseline and Day 14 ]

10.  Secondary:   Mean Change in Neurological Exam Score From Baseline - Day 42   [ Time Frame: Baseline and Day 42 ]

11.  Secondary:   Mean Change in Neurological Exam Score From Baseline - Day 70   [ Time Frame: Baseline and Day 70 ]

12.  Secondary:   Mean Change in Neurological Exam Score From Baseline - Day 168   [ Time Frame: Baseline and Day 168 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Peter G. Pappas, MD
Organization: University of Alabama at Birmingham
phone: 205-934-9951
e-mail: pappas@uab.edu


Publications of Results:

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00145249     History of Changes
Other Study ID Numbers: 03-154, BAMSG 3-01
Study First Received: September 2, 2005
Results First Received: March 18, 2010
Last Updated: May 10, 2012
Health Authority: Thailand: Ethical Committee
United States: Federal Government
United States: Food and Drug Administration
United States: Institutional Review Board